高级别胶质瘤疾病轨迹中的姑息治疗转诊
回顾性分析2011年8月1日至2020年1月23日一家大型学术机构多中心癌症登记中621例WHO III或IV级高级别胶质瘤患者,134例(21.58%)接受姑息治疗咨询,其中111例(82.84%)在住院期间发生;仅14例(10.45%)在诊断期转诊,65例(48.51%)在临终期转诊;多变量逻辑回归仅Charlson合并症指数较高与姑息治疗咨询几率增加相关(OR 1.3,95%CI 1.2-1.4,p<0.01);临终期前接受咨询者自诊断起生存期长于临终期转诊者(16.5个月 vs 11个月,p<0.01)。
要点
- 621例高级别胶质瘤患者中仅134例(21.58%)接受姑息治疗咨询,其中82.84%在住院期间发生。
- 仅10.45%在诊断期转诊,48.51%在临终期转诊,约十分之一患者可能获得早期姑息治疗获益。
- 临终期前接受姑息治疗咨询者自诊断起生存期长于临终期转诊者(16.5个月 vs 11个月,p<0.01)。
核心结论
- 少数高级别胶质瘤患者曾接受姑息治疗咨询,主要发生在住院环境,近半数在临终期;整个队列中仅约十分之一患者可能获得早期姑息治疗咨询的获益,尽管早期转诊与更长生存期相关。
- 需要进一步研究阐明高级别胶质瘤早期姑息治疗咨询的障碍和促进因素。
研究设计与样本
- 回顾性研究,从多中心医疗系统癌症登记中识别2011年8月1日至2020年1月23日期间接受诊疗的高级别胶质瘤患者,按是否接受姑息治疗咨询及初始咨询时机(诊断期、初始治疗期、二线治疗期、临终期)分层。
主要发现
- 621例高级别胶质瘤患者中134例(21.58%)接受姑息治疗咨询,其中111例(82.84%)在住院期间发生。
- 134例中,诊断期转诊14例(10.45%),初始治疗期35例(26.12%),二线治疗期20例(14.93%),临终期65例(48.51%)。
- 多变量逻辑回归中,仅Charlson合并症指数较高与姑息治疗咨询几率增加相关(OR 1.3,95%CI 1.2-1.4,p<0.01),年龄或组织病理学无关联。
- 临终期前接受姑息治疗咨询者自诊断起生存期长于临终期转诊者(16.5个月 vs 11个月,p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adults with high-grade glioma (HGG), WHO grade III or IV, have substantial palliative care needs. Our aim was to determine occurrence, timing, and factors associated with palliative care consultation (PCC) in HGG at one large academic institution. METHODS: HGG patients receiving care between 08/1/2011 and 01/23/2020 were identified retrospectively from a multi-center healthcare system cancer registry. Patients were stratified by any PCC (yes/no), and timing of initial PCC by disease phase: diagnosis (before radiation), during initial treatment (first-line chemotherapy/radiation), second-line treatment(s), or end-of-life (after last chemotherapy). RESULTS: Of 621 HGG patients, 134 (21.58%) received PCC with the vast majority occurring during hospital admission [111 (82.84%)]. Of the 134, 14 (10.45%) were referred during the diagnostic phase; 35 (26.12%) during initial treatment; 20 (14.93%) during second-line treatment; and 65 (48.51%) during end of life. In multivariable logistic regression, only higher Charlson Comorbidity Index was associated with greater odds of PCC [OR 1.3 (95% CI 1.2-1.4), p < 0.01]; but not age or histopathology. Patients who received PCC prior to end of life had longer survival from diagnosis than those referred during end of life [16.5 (8, 24) months vs. 11 (4, 17); p < 0.01]. CONCLUSION: A minority of HGG patients ever received PCC, which primarily occurred in the inpatient setting, and nearly half during the end-of-life phase. Thus, only about one in ten patients in the entire cohort potentially received the benefits of earlier PCC despite earlier referral having an association with longer survival. Further studies should elucidate barriers and facilitators to early PCC in HGG.
引用
- Crooms RC, Taylor JW, Jette N, et al. Palliative care referral across the disease trajectory in high-grade glioma. J Neurooncol. 2023. PMID: 37209290. doi:10.1007/s11060-023-04338-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。